Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

293
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

341
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
341
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

392
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Autism Spectrum Disorder01:19

Autism Spectrum Disorder

1.4K
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
1.4K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

387
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atopic Dermatitis Across the Lifespan: Understanding, Measuring and Minimizing Cumulative Life Course Impairment.

Acta dermato-venereologica·2026
Same author

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.

JAMA dermatology·2026
Same author

SOX9/Kruppel-like factor 5 and the infiltrating epidermal hyperplasia of hidradenitis suppurativa.

Journal of the American Academy of Dermatology·2026
Same author

Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa: a prospective observational study.

Frontiers in immunology·2026
Same author

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.

Dermatology and therapy·2025
Same author

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension.

Journal of the American Academy of Dermatology·2025
Same journal

GLP-1 Receptor Agonists in Hidradenitis Suppurativa-Emerging Opportunities for Comorbidity Management?

JAMA dermatology·2026
Same journal

Topical Preparations for Moderate to Severe Rosacea Treatment: A Systematic Review and Network Meta-Analysis.

JAMA dermatology·2026
Same journal

GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa.

JAMA dermatology·2026
Same journal

BRAF Inhibition in Congenital Nevi and Neural Melanosis.

JAMA dermatology·2026
Same journal

The Absent Original in Smartphone Photography.

JAMA dermatology·2026
Same journal

A Tribute to a Master Clinician: Richard Odom.

JAMA dermatology·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

969

Pediatric Psoriasis Comorbidity Screening Guidelines.

Emily Osier1, Audrey S Wang2, Megha M Tollefson3

  • 1Department of Dermatology, Eastern Virginia Medical School, Norfolk.

JAMA Dermatology
|May 18, 2017
PubMed
Summary
This summary is machine-generated.

Pediatric psoriasis patients require routine screening for associated health conditions. These new guidelines aim to identify risks early, improving long-term health outcomes for children with psoriasis.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 2, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

969
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.7K

Area of Science:

  • Pediatric Dermatology
  • Inflammatory Skin Diseases
  • Comorbidity Screening

Background:

  • Psoriasis in children is linked to significant comorbidities affecting long-term health.
  • Early identification of risk factors is crucial for managing pediatric psoriasis.
  • Associated conditions include obesity, arthritis, and mental health issues.

Purpose of the Study:

  • To establish the first evidence-based guidelines for screening comorbidities in pediatric psoriasis.
  • To provide healthcare professionals with a framework for managing associated risks.

Main Methods:

  • A comprehensive literature review was conducted from 1999 to 2015.
  • Expert panel utilized the Strength of Recommendation Taxonomy (SORT) to evaluate evidence quality.
  • Multidisciplinary panel included specialists in dermatology, rheumatology, gastroenterology, endocrinology, and cardiology.

Main Results:

  • Limited pediatric-specific studies resulted in SORT level C expert consensus recommendations.
  • Recommendations align with general pediatric guidelines but emphasize arthritis, depression, and anxiety screening.
  • Key areas for future research were identified.

Conclusions:

  • Routine screening for comorbidities is essential for pediatric psoriasis patients.
  • Guidelines are intended for all healthcare providers managing pediatric psoriasis.
  • Future research and guideline refinement are necessary as more data becomes available.